[Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]. 1984

M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi

We evaluated whether assay of tissue polypeptide antigen (TPA) in sera is valuable for the determination of cancer stages compared to other tumor markers such as CEA, AFP, beta2-microglobulin, ferritin, and elastase-1. The study population consisted of cancer patients (33 gastric cancers, 7 colo-rectal cancers and 15 hepatomas), 169 patients with benign gastro-enteric diseases and 72 healthy volunteers. The percentage of positive cases for TPA (higher than 200 u/l) was 61% in gastric cancer, 71% in colo-rectal cancer and 87% in hepatoma. In certain non-cancerous conditions, such as gastric ulcer (active stage), acute hepatitis and chronic hepatitis, the TPA levels were increased over the level of healthy volunteers. There was no significant correlation between TPA and the other tumor markers. Our study suggests that TPA may be useful in the identification and evaluation of cancer patients.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D005260 Female Females
D005293 Ferritins Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types. Basic Isoferritin,Ferritin,Isoferritin,Isoferritin, Basic

Related Publications

M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
December 1983, Radioisotopes,
M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
October 1984, Nihon Sanka Fujinka Gakkai zasshi,
M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
January 1996, Anticancer research,
M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
January 1994, Cancer,
M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
February 1982, Medicina clinica,
M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
April 1986, Minerva medica,
M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
M Kanauchi, and F Sawai, and T Saito, and F Yumura, and K Kanauchi, and T Hamaguchi, and Y Hara, and K Yoshimura, and K Nishiura, and K Dohi
September 1984, Neurologia medico-chirurgica,
Copied contents to your clipboard!